Norflex (Orphenadrine Citrate)

Orphenadrine citrate blocks central muscarinic receptors and has antihistaminic activity. This anticholinergic action reduces neuronal excitability in the central nervous system, producing a generalized relaxation of skeletal muscles and diminishing the perception of pain.

The dosage of Norflex is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Only a qualified health professional should set the appropriate dose and administration schedule.

The safety of orphenadrine citrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a health‑care provider.

To request Norflex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Norflex (orphenadrine citrate) is distinguished by its combined anticholinergic and antihistaminic properties, offering both muscle relaxation and analgesic effects. Compared with purely centrally acting agents such as cyclobenzaprine, it may produce more pronounced anticholinergic side effects but can be advantageous when concurrent antihistaminic action is desired.

Norflex should be stored below 25 °C in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and efficacy.

Norflex is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and rate of infusion are determined by the prescribing clinician and should be performed by qualified health‑care personnel.

Serious adverse events, although rare, include cardiac arrhythmias, severe hypotension, anaphylactic reactions, hepatotoxicity, and neuroleptic‑malignant‑like syndrome. Patients should be monitored for any signs of these conditions, and treatment should be discontinued immediately if they occur.

Norflex is contraindicated in patients with known hypersensitivity to orphenadrine or any excipients, those taking monoamine oxidase inhibitors, and individuals with narrow‑angle glaucoma or severe urinary retention. Caution is also advised for the elderly and patients with significant hepatic or renal impairment.